What Is Regencell Bioscience Holdings L (RGC) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Regencell Bioscience Holdings L's intrinsic value is estimated at $4.92, presenting a divided outlook at the current price of $5.13. With an average implied return of -3.9% across a split 4–4 (bull–bear) consensus, the model spread of +216.3% underscores analytical uncertainty. Notably, EPV sees the most upside at +116.4% (fair value: $11.09), while Dynamic NAV is the most conservative at -99.9% ($0.01). The spread between these extremes — +216.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About RGC?
9 of 13 models are currently active for RGC. Of these, 5 models suggest upside while 4 models suggest overvaluation. The Bayesian DCF estimates RGC's intrinsic value at $1.91, implying -62.8% downside from the current price. See which stocks rank higher →
How Does RGC Rank in Medicinal Chemicals & Botanical Products?
Among 17 Medicinal Chemicals & Botanical Products stocks, RGC ranks #13 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.
Regencell Bioscience Holdings L's positioning within the Medicinal Chemicals & Botanical Products segment means that book-to-bill ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including automation and productivity gains — shape both the opportunity set and risk profile.
Is RGC a Value Trap?
CirclFi's Value Trap algorithm assigns RGC a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Regencell Bioscience Holdings L. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Regencell Bioscience Holdings L scores 4.6 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +216.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RGC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RGC's 9 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad